Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial
Clinical Snapshot
PICO Framework
| P — Population | Patients with unprotected left main coronary artery stenosis (≥50% diameter stenosis or FFR ≤0.80) eligible for both PCI and CABG, with chronic or acute coronary syndrome and life expectancy >1 year |
| I — Intervention | Percutaneous coronary intervention with newer generation drug-eluting stents |
| C — Comparator | Coronary artery bypass grafting |
| O — Outcomes | Primary: 10-year all-cause mortality. Secondary outcomes not fully detailed in abstract |
Bottom Line
This landmark 10-year follow-up of the NOBLE trial demonstrates non-inferiority of PCI compared to CABG for unprotected left main coronary artery disease, with identical long-term mortality outcomes (23% vs 25%, HR 0.93, 95% CI 0.74-1.18, p=0.56). The study enrolled 1,201 patients across multiple European centres, with robust methodology including heart team eligibility assessment and stratified randomisation. While the open-label design introduces some bias risk, the large sample size, minimal loss to follow-up, and intention-to-treat analysis strengthen the findings. These results support PCI as a viable alternative to CABG for appropriately selected patients with left main disease, particularly those without additional complex lesions. The findings will inform heart team discussions and patient-centred decision making, though individual patient factors including anatomy complexity, surgical risk, and patient preferences remain crucial considerations. Australian clinicians can apply these results confidently, as both interventions are well-established and funded within our healthcare system.
Key Findings
P Value: p=0.56 (non-significant)
Effect Size: Hazard ratio 0.93 favouring PCI
Primary Outcome: 10-year all-cause mortality: PCI 23% vs CABG 25%
Nnt Or Sensitivity: Non-inferiority demonstrated - PCI not inferior to CABG for mortality
Confidence Interval: 95% CI 0.74-1.18
Clinical Application
High feasibility in tertiary cardiac centres with experienced interventional cardiologists and cardiac surgeons Relevant to Australian practice - both procedures PBS-funded, aligns with CSANZ guidelines emphasising heart team approach for left main disease Patients with unprotected left main stenosis suitable for both PCI and CABG, particularly those without complex additional lesions
Abstract
BACKGROUND: Coronary artery bypass grafting (CABG) is recommended over percutaneous coronary intervention (PCI) for patients with significant unprotected left main coronary artery disease. We aim to provide long-term outcome data comparing PCI with newer generation drug-eluting stents and CABG, which are scarce. METHODS: This previously published, prospective, randomised, open-label, non-inferiority trial enrolled patients with unprotected left main coronary artery stenosis at 36 hospitals in Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Norway, Sweden, and the UK. Eligibility was determined by a multidisciplinary heart team and defined by clinical criteria (chronic or acute coronary syndrome and a life expectancy of >1 year) and angiographic criteria (left main coronary artery diameter stenosis ≥50% or fractional flow reserve ≤0·80 in the left main ostium, mid-shaft, or bifurcation). Patients with ST elevation myocardial infarction within 24 h or considered at too high risk for CABG or PCI were excluded. Patients with angiographically confirmed significant left main coronary artery disease were randomly assigned (1:1) to PCI or CABG using an online system and stratified by site, sex, distal left main coronary artery bifurcation lesions, and diabetes. The primary outcome was the difference in 10-year all-cause mortality in the intention-to-treat (ITT) population, which was analysed using Kaplan-Meier estimates and unadjusted Cox regression. Patients were censored at the date of death, emigration, withdrawal, or loss to follow-up. Variation in all-cause mortality was assessed in prespecified subgroups. The trial is registered with ClinicalTrials.gov, NCT01496651 (active, not recruiting). FINDINGS: From Dec 9, 2008, to Jan 21, 2015, 1201 patients were randomly assigned to PCI (n=598) or CABG (n=603). 17 patients were lost to follow-up before 1 year. 592 patients in each group were included in the ITT population. Mean age was 66·2 years (SD 9·9) in the PCI group and 66·2 years (9·4) in the CABG group. 256 (22%) of 1184 participants were female and 928 (78%) were male. There was no difference in all-cause mortality at 10 years (136 [23%] of 592 in the PCI group and 145 [25%] of 592 in the CABG group; hazard ratio 0·93 [95% CI 0·74-1·18]; p=0·56). No significant difference in all-cause mortality with SYNTAX score was identified. INTERPRETATION: There was no significant difference in all-cause mortality at 10 years between PCI and CABG for patients with unprotected left main coronary artery disease and no additional complex lesions, indicating that PCI is equally as safe as CABG in patients eligible for both treatments. These results will aid heart teams in developing an individualised patient-centred strategy. FUNDING: Biosensors and Aarhus University Hospital.
References
- 1.Holck, E. N., Holm, N. R., Hildick-Smith, D., Lindsay, M. M., Spence, M. S., Erglis, A., Menown, I. B. A., Steigen, T., Hune Mogensen, L. J., Modrau, I. S., Niemelä, M., Lassen, J. F., Oldroyd, K., Stradins, P., Walsh, S. J., Endresen, P. C., Trovik, T., Fröbert, O., Graham, A. N. J., Anttila, V., Trivedi, U., Thuesen, L., & Christiansen, E. H. (2026). Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. *Lancet*, Article 10.1016/S0140-6736(26)00205-9. https://doi.org/10.1016/S0140-6736(26)00205-9
Related Research
The American journal of cardiology
Systematic Review of Coronary Computed Tomography Angiography Guidance for Chronic Total Occlusion Percutaneous Coronary Intervention
18 July 2026
Medicine
Molecular profiling of coronary stent restenosis: A systematic review and functional analysis of implicated genes
28 June 2026
Cardiovascular research
Proteins targeting ischaemic-reperfusion injury and repair after myocardial infarction: a systematic literature review.
28 June 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service